The Latest Cardiac and Vascular News
– Abbott’s investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart – Proprietary implant-to-implant (i2i™) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate – Aveir DR is also specifically […]
SINGAPORE, Feb. 4, 2022 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. The acquisition means that Genesis […]
DUBLIN–(BUSINESS WIRE)–CroíValve, a Dublin based medical device company developing a novel treatment for tricuspid regurgitation, has raised a Series A round to fund a Feasibility clinical study with its DUO Coaptation Valve system. This novel approach to treating tricuspid regurgitation combines the best of repair and replacement to provide the […]
New Research From Included Health Finds Virtual Care With a Holistic Approach Controls Blood Pressure SAN FRANCISCO–(BUSINESS WIRE)–According to a new study published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes, utilizing virtual care visits to manage hypertensive patients demonstrated an improvement in blood pressure in 77 percent of patients. According […]
TARRYTOWN, N.Y., Feb. 4, 2022 /PRNewswire/ — Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV®(2); revenues excluding REGEN-COV(1) increased 17% Full year 2021 revenues increased 89% to $16.07 billion compared to full year 2020 including $6.19 billion attributable to REGEN-COV(2); revenues excluding REGEN-COV(1) increased 19% Fourth quarter 2021 EYLEA® U.S. net sales increased 15% to $1.55 […]
VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc Reducer™ (“Reducer”). The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University […]
PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and […]
Reports Fourth Quarter Revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83; Posts Full-Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51 Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios Advances Pipeline with […]
Conference Call Scheduled for Today, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.1 million increased 1.3% sequentially compared to first quarter this year and decreased 7.8% compared to second quarter last year Procedure volumes adversely impacted by hospital constraints and staffing shortages caused by Covid-19 […]
STOCKHOLM, Feb. 3, 2022 /PRNewswire/ — Continued strength with net sales growth above 30% despite the pandemic Fourth quarter (October-December 2021) Order intake amounted to 73.7 (73.1) MSEK. Net sales amounted to 67.7 (45.9) MSEK. Operating income for the period before depreciations (EBITDA) totalled 12.0 (4.3) MSEK. Net income for the period amounted […]
